Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | AKT2 | P31751 | 12/20 | 0.44 |
| ▸ | AKT1 | P31749 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 3/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491439 | 0.89 | LMNA (0.42) | AKT1ROCK2KIT | |
| SCHEMBL3491075 | 0.89 | CNR1 (0.36) | JAK3AKT2CYP2C9KIT | |
| SCHEMBL3489441 | 0.87 | AKT2 (0.47) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL3490469 | 0.83 | AKT2 (0.45) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL3489438 | 0.83 | AKT2 (0.44) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL3488975 | 0.80 | AKT1 (0.50) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL390884 | 0.80 | JAK3 (0.58) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL31374403 | 0.80 | JAK3 (0.58) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL3489794 | 0.79 | JAK3 (0.47) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL3490514 | 0.77 | ROCK2 (0.42) | ROCK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | JAK3 225/4885AKT2 35/4885AKT1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.